Article
A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death.
All News
Article
BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.
Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. We also have two call-in cases on "Ask Cush Anything".
Be sure to join in the fun at RNL 2025 next weekend - Gong Show Karaoke; what will you sing?
Article
The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.
Article
A large cohort of 18-year-old Swedish males were followed longitudinally for cardiovascular, respiratory, and musculoskeletal outcomes.
Article
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib
Article
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated.
Article
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.
Article
Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice variance exists.
Dr. John Cush
Tweet
Rituximab is FDA approved for treatment of moderate to severe pemphigus, but 20% may relapse in 1st Yr. Study of 87 pts shows the efficacy of repeat 6 mos RTX in A) those with persistent Dz activity and B) anyone w/ predictors of relapse (PDAI score, DSG1 or DSG3 abs)… https://t.co/IhqdGWVcdp https://t.co/MKhDpa5zHv
Dr. John Cush
Tweet
Dannish study of 1 million infants, exposed vs unexposed to systemic glucocorticoids shows prenatal GC exposure assoc w/ higher risk of autism (RR 1.5), intellectual disability (1.3), ADHD (1.3), mood/anxiety (1.3). Same risk for 290K mothers w/ autoimmune/inflamm Dz… https://t.co/bXL3YqCIYZ https://t.co/psNVENXRPs
Dr. John Cush
Tweet
Celecoxib Lowers Colon Cancer Recurrence Risk
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to… https://t.co/tIoMtRlwKt https://t.co/fzOAplwJLi
Dr. John Cush
Tweet
UK NHS 2023-24 figures show hospitalization for SLE is 8X more common in blacks (62.6 per 100,000) compared to white SLE (7.8/100K) and Asian SLE (26/100K), Lupus hospitalizations risen 50% in 4 yrs (6,334 to 8,006 in 2023-24). Is this “stark” inequality from delayed Dx?… https://t.co/NDdIkWKZy5 https://t.co/E4Fmvz9uLn
Dr. John Cush
Tweet
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/xKy7JY7pPr https://t.co/VYrDMQcjHc
Dr. John Cush
Tweet
ACR Applauds Second Round of Medicare Drug Price Negotiations
The ACR applauded the announcement of additional drugs subject to pricing negotiations with the CMS. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare… https://t.co/z1LkpWMXqg https://t.co/hqjkqTqJxw
Dr. John Cush
Tweet
SubAnalysis of STOP Gout Trial: 277 pts w/ CKD received either allopurinol or febuxostat. Most achieved SUA goal (79% vs 81%), fewer allopurinol pts had gout flares (32% vs 45%; P=0.02); AKI only seen stage w/ 3 CKD (allopurinol > febuxostat) https://t.co/wwfVCei4Ej https://t.co/W8Y7KxcSd4
Dr. John Cush
Tweet
Open label trial of starting MTX in 11 uncontrolled gout pts previously Rx w/ IV pegloticase (PEG 2-27x) showed if gout pts failed PEG monotherapy, only 1/11 (9%) showed a good response to adding MTX w/ PEG. MTX must be started w/ PEG initiation to work https://t.co/aoBtyIRbQe https://t.co/RNe03O6Z1N
Dr. John Cush
Tweet
Febuxostat (ULORIC) is discontinued by the manufacturer in the USA. This week an FDA update on drug shortages list announced Uloric has been discontinued. Takeda sited dropping sales, generic competition, and CV safety concerns in the last decade. GENERIC febuxostat should still… https://t.co/QcUNCUFfvJ https://t.co/oBdwkcN177
Dr. John Cush
Tweet
post hoc analysis of 4 registration trials of pegloticase, show rates of MACE and Thromboembolic Events were Infrequent (<1.5%; 35.4 events/1000 PY), similar to general gout population (31.7 events/1000 person-years) https://t.co/v6ZqtL4yB2 https://t.co/NA0j20Oew2
Dr. John Cush
Tweet
Systematic review of 14 studies using administrative/med. records data on >130 million people & 1 million dementia cases, finds the risk of Alzheimers/Dementia reduced w/ Antimicrobials, vaccines & NSAID antiinflammatories (but incr w/ DM drugs, vitamins, antipsychotics)… https://t.co/p79s5Pw4k2 https://t.co/9DO1WO2NuG
